There are 717 resources available
Conclusion
Presenter: Michel Sadelain
Session: Hopes and limitations for CRISPR technology in cancer (in collaboration with AACR)
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Fatima Cardoso
Session: Genetic testing for hereditary breast cancer and therapeutic implications
Resources:
Webcast
LIVE Q&A
Presenter: Alexandre Chan
Session: Side effect management of old and new anti-tumour agents: ESMO Guidelines into practice
Resources:
Webcast
LIVE Q&A
Presenter: Myung-Ju Ahn
Session: Are large NGS panels really changing patient outcomes?
Resources:
Webcast
Checkpoint inhibitors: How to manage rare and life threatening irAE
Presenter: Christina Ruhlmann
Session: Side effect management of old and new anti-tumour agents: ESMO Guidelines into practice
Resources:
Slides
Webcast
Acute toxicity: Side-effect management of conventional chemotherapeutic agents
Presenter: Florian Scotté
Session: Side effect management of old and new anti-tumour agents: ESMO Guidelines into practice
Resources:
Slides
Webcast
Updates in oncological emergencies
Presenter: Alexandre Chan
Session: Side effect management of old and new anti-tumour agents: ESMO Guidelines into practice
Resources:
Slides
Webcast
Several potential new targets are missed regarding current guidelines
Presenter: Fabrice Barlesi
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast
Are the addition of these new targets really changing patient outcomes globally?
Presenter: Jürgen Wolf
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast
Designing a pragmatic strategy for adequately genotyping advanced NSCLC
Presenter: Myung-Ju Ahn
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast